

David Jilich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5334889/publications.pdf>

Version: 2024-02-01

20
papers

337
citations

1163117

8
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

739
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV care in times of the COVID-19 crisis – Where are we now in Central and Eastern Europe?. <i>International Journal of Infectious Diseases</i> , 2020, 96, 311-314.	3.3	76
2	Development of 5- LTR DNA methylation of latent HIV-1 provirus in cell line models and in long-term-infected individuals. <i>Clinical Epigenetics</i> , 2016, 8, 19.	4.1	54
3	Incidence, immunological and clinical characteristics of reactivation of latent <i>Toxoplasma gondii</i> infection in HIV-infected patients. <i>Epidemiology and Infection</i> , 2015, 143, 600-607.	2.1	52
4	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μ L: secondary outcome results from a randomised controlled trial. <i>Lancet HIV</i> , 2017, 4, e105-e112.	4.7	44
5	HIV care in Central and Eastern Europe: How close are we to the target?. <i>International Journal of Infectious Diseases</i> , 2018, 70, 121-130.	3.3	37
6	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14
7	The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease – A report from Central and Eastern Europe. <i>International Journal of Infectious Diseases</i> , 2021, 104, 293-296.	3.3	14
8	The Effect of Latent <i>Toxoplasma gondii</i> Infection on the Immune Response in HIV-Infected Patients. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	8
9	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	2.2	8
10	National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region. <i>HIV Medicine</i> , 2022, 23, 546-552.	2.2	7
11	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018, 19, 102-117.	2.2	6
12	Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART. <i>Viruses</i> , 2018, 10, 154.	3.3	4
13	Cross-sectional study on vaccination coverage in newly diagnosed HIV-infected persons in the Czech Republic. <i>Central European Journal of Public Health</i> , 2019, 27, 217-222.	1.1	3
14	The Presence of Either Typical or Atypical Radiological Changes Predicts Poor COVID-19 Outcomes in HIV-Positive Patients from a Multinational Observational Study: Data from Euroguidelines in Central and Eastern Europe Network Group. <i>Viruses</i> , 2022, 14, 972.	3.3	3
15	First reported case of chancroid in the Czech Republic. <i>International Journal of STD and AIDS</i> , 2018, 29, 1127-1129.	1.1	2
16	Prevalence of Human Leukocyte Antigen (HLA)-B*5701 in HIV-infected Subjects in Czech Republic. <i>Central European Journal of Public Health</i> , 2011, 19, 128-130.	1.1	2
17	Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons. <i>Epidemiology and Infection</i> , 2021, 149, e41.	2.1	1
18	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.9	1

#	ARTICLE	IF	CITATIONS
19	Scanning Laser Polarimetry in Human Immunodeficiency Virus-Infected Patients. Neuro-Ophthalmology, 2011, 35, 187-190.	1.0	0
20	Retrospective evaluation of an observational cohort by the Central and Eastern Europe Network Group shows a high frequency of potential drug-drug interactions among HIV-positive patients receiving treatment for coronavirus disease 2019 (COVID-19). HIV Medicine, 2021, , .	2.2	0